Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-05-02 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Board Meeting — GLAND PHARMA LIMITEDhas informed the Exchange about Board Meeting to be held on 18-May-2023to inter-alia consider and approve the Audited financial results of the Company for the Year…
Regulatory Filings
2023-05-02 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter dated April 28, 2023, addressed to stock exchanges, informing about a scheduled Board Meeting on May 18, 2023, to consider and approve audited financial results for the quarter and financial year ended March 31, 2023. It also mentions the trading window closure and reopening dates and that details of an earnings call will be provided later. The document is an announcement of an upcoming board meeting and related events, not the financial results or earnings release themselves. The document length is short (1861 characters) and serves as a notification rather than containing substantive financial data or the actual report. Therefore, it fits the category of Board/Management Information (MANG) as it relates to board meeting intimation and compliance with SEBI regulations.
2023-04-28 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the completion of an acquisition by Gland Pharma Limited. It references prior intimations and provides details about the acquisition completion date and the entities involved. The document cites compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a corporate transaction (acquisition) rather than a full report or detailed financial statements. It does not contain financial data or detailed analysis but serves as an update on a capital transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the acquisition completion notice, not a full merger filing or detailed merger proxy statement, so it is not classified under M&A Activity or Merger & Acquisition filings.
2023-04-27 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter from the company to the National Stock Exchange of India addressing a query about an increase in trading volume of its shares. It explicitly states that there is no information requiring disclosure under Regulation 30 of the SEBI Listing Regulations and that the company is unable to comment on the volume increase since shares are freely traded. The document is a regulatory communication clarifying a market surveillance inquiry rather than a financial report, announcement of voting results, or management information. It does not contain financial data, report publication, or executive changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2023-04-20 English
Updates
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the appointment of new statutory auditors. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and provides details about the appointment of Deloitte Haskins & Sells as statutory auditors for a five-year term starting from the upcoming Annual General Meeting. The content is an announcement of a board decision about auditor appointment, not the audit report itself or any financial statements. The document length is short (2728 characters) and it serves as an intimation to regulators and shareholders. Therefore, it fits the category of Board/Management Information (MANG), which includes announcements of changes in company management or board-related appointments.
2023-03-29 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a notification addressed to stock exchanges about the allotment of equity shares due to the exercise of Employee Stock Options (ESOP). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the number of shares allotted and the date. The content is an announcement of a capital change event (allotment of shares) rather than a full financial report or detailed analysis. The document length is short (1443 characters), and it does not contain financial statements or management discussion. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-03-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.